Table 3.

The relationships between antiplatelet agent use and 5-year rate of hemorrhagic stroke recurrence among patients with first-time hemorrhagic stroke (n = 7589).

Variables	Number	Number of HS event	Person-years	Incidence rate per 100 person-years	Crude HR (95% CI)	Adjusted HR (95% CI)
Age
20–44	970	70	4259.6	1.64	Ref	Ref
45–59	2704	202	11,294.0	1.79	1.07 (0.82–1.41)	0.93 (0.70–1.23)
≥ 60	3915	260	13,318.7	1.95	1.11 (0.86–1.45)	1.09 (0.90–1.32)
Sex
Female	2978	208	11,381.1	1.83	Ref	Ref
Male	4611	324	17,491.3	1.85	1.01 (0.85–1.20)	1.00 (0.84–1.19)
Length of stay, days
< 9	1831	134	7485.4	1.79	Ref	Ref
≥ 9	5758	398	21,386.9	1.86	1.03 (0.84–1.25)	1.00 (0.82–1.23)
ICU
No	6036	427	23,614.7	1.81	Ref	Ref
Yes	1553	105	5257.6	2.00	1.08 (0.87–1.34)	0.99 (0.93–1.06)
CCI
< 5	5029	392	20,121.6	1.95	Ref	Ref
≥ 5	2560	140	8750.7	1.60	0.78 (0.65–0.95)	0.79 (0.64–0.98)
Antiplatelet agents
No	5529	431	19,990.5	2.16	Ref	Ref
Yes	2060	101	8881.8	1.14	0.54 (0.44–0.67)	0.53 (0.42–0.66)
Diabetes mellitus
No	5251	390	20,459.9	1.91	Ref	Ref
Yes	2338	142	8412.4	1.69	0.86 (0.71–1.05)	0.97 (0.79–1.20)
Hypertension
No	842	39	3237.6	1.20	Ref	Ref
Yes	6747	493	25,634.7	1.92	1.57 (1.13–2.17)	1.87 (1.32–2.64)
Hyperlipidemia
No	5250	392	19,453.8	2.02	Ref	Ref
Yes	2339	140	9418.5	1.49	0.75 (0.62–0.91)	0.78 (0.64–0.96)
AF
No	7269	510	27,910.2	1.83	Ref	Ref
Yes	320	22	962.1	2.29	1.16 (0.76–1.78)	1.32 (0.85–2.04)
CVD
No	5587	419	21,742.8	1.93	Ref	Ref
Yes	2002	113	7129.5	1.58	0.80 (0.65–0.99)	0.89 (0.71–1.11)
CHF
No	4164	307	16,216.6	1.89	Ref	Ref
Yes	3425	225	12,655.8	1.78	0.92 (0.78–1.09)	0.96 (0.80–1.16)
The history of IS
No	7272	513	27,966.0	1.83	Ref	Ref
Yes	317	19	906.3	2.10	1.06 (0.67–1.67)	1.14 (0.72–1.82)

ICU, intensive care unit; CI, confidence interval; AF, atrial fibrillation; CHF, congestive heart failure; IS, ischemic stroke; HS, hemorrhagic stroke; CVD, cardiovascular disease.